TVGN (Tevogen Bio Holdings) Common Stock : $0.02 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Tevogen Bio Holdings Common Stock?

Tevogen Bio Holdings's quarterly common stock stayed the same from Jun. 2024 ($0.02 Mil) to Sep. 2024 ($0.02 Mil) but then increased from Sep. 2024 ($0.02 Mil) to Dec. 2024 ($0.02 Mil).

Tevogen Bio Holdings's annual common stock declined from Dec. 2022 ($356.87 Mil) to Dec. 2023 ($0.01 Mil) but then increased from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.02 Mil).

Tevogen Bio Holdings Common Stock Historical Data

The historical data trend for Tevogen Bio Holdings's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tevogen Bio Holdings Common Stock Chart

Tevogen Bio Holdings Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Common Stock

0.06

356.87

0.01

0.02

Tevogen Bio Holdings Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Common Stock	Get a 7-Day Free Trial					0.01	0.02	0.02	0.02	0.02

Tevogen Bio Holdings Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Tevogen Bio Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tevogen Bio Holdings Inc (NAS:TVGN) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

G28:Germany

Address

15 Independence Boulevard, Warren, NJ, USA, 07059

Website

https://www.tevogen.com

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.